An NCI-Designated Cancer Center
Everyone knows someone impacted by cancer. One in two men and one in three women will be diagnosed with cancer in their lifetime. Worldwide, cancer rates are expected to increase by as much as 63 percent by 2040.
Current therapies remain insufficient to address the threat. Through innovative biomedical expertise and collaborations, the Salk Cancer Center is working to develop new therapies and cures to enhance the lives of current and future generations.
Salk’s Conquering Cancer Initiative is a scientific and philanthropic initiative to bring together scientists in collaboration to harness new strategies against five deadly cancers: pancreatic, ovarian, lung, brain (glioblastoma) and triple negative breast. Together, Salk researchers will identify cancer’s vulnerabilities and find new methods to attack tumors and leave healthy tissues alone. Our Conquering Cancer Initiative launched in April 2018 and we are pleased to share our Year Two Progress report thanks to supporters and collaborators who serve as our valued partners.
We are at a unique and momentous time in cancer research. We invite you to be a part of our Conquering Cancer Initiative.
Matching Your Gift Dollar for Dollar
The Salk Institute is recruiting a new Assistant Professor, Dr. Christina Towers, to the Salk Cancer Center. In honor of the Conquering Cancer Initiative, the BioMed Realty Management Team is issuing a challenge match – they will match, dollar for dollar, up to $1M to support Towers’ recruitment and to support her research and that of the Salk Cancer Center. BioMed’s president and CEO, Tim Schoen, is a Salk trustee and chairman of the Institute’s Conquering Cancer Initiative Advisory Committee.
read more about the
Conquering Cancer Initiative
Sandy Liarakos, CFRE
Senior Director of External Relations
Wednesday Cancer Center Trainee Seminar Series
Date: Wednesday, May 19, 2021
Time: 12:00 p.m.
Speaker/Title: Meredith Frie, PhD (Zheng Lab): “Zap70 as an immunotherapeutic target to improve anti-tumor T cell activity against low-affinity neoantigens”
Speaker/Title: Mara Gilardi, PhD (Hollern Lab): “Tunable engineering solution to study cancer”
Hosts: Leona Flores
Executive Director, Salk Cancer Center
Location: Zoom link
Contact: Leona Flores, PhD, firstname.lastname@example.org
Did you know that Salk Cancer Center has been leading the way in conquering cancer since 1970? Find Out How »